IDH1 and central nervous system cancer: Here, we provide evidence that RNaseH2 inhibitor candidates can reduce glioma cell survival, particularly in high-grade gliomas with IDH1 wild-type status, a subtype characterized by its aggressiveness and treatment resistance.